Table 6.
Relevant clinical trials evaluating cancer vaccines for NSCLC. *N.S.: Not Specified
| Vaccine | Components (Brand/Clinical Trial Name) | NSCLC Stage | Clinical Study Phase | Clinical Trial |
|---|---|---|---|---|
| Cellular vaccine | Allogenic tumoral cells (1650-G) | I–II | II |
NCT00654030, NCT00601796 |
| Autologous engineered dendritic cells (MIDRIX4-LUNG) | III | I | NCT04082182 | |
| Autologous mRNA/DNA transfected dendritic cells (MIDRIXNEO-LUNG) | III–IV | I | NCT04078269 | |
| Allogenic mRNA-transfected dendritic cells (AST-VAC2) | III–IV | I | NCT03371485 | |
| Allogenic engineered dendritic cells irradiated with seven active agents (NY-ESO-1, MAGE C1, 4MAGE C2, TPGB, Survivn, MUC1, Melan-A antigen (PDC*lung01) | N.S. | I–II | NCT03970746 | |
| Autologous dendritic cells pulsed with allogenic tumor cells | III | II | NCT00103116 | |
| Allogenic whole tumor cells (Lucanix ®) |
III–IV | III | NCT00676507, NCT01058785 | |
| Autologous dendritic cells pulsed with allogenic tumor cells (MelCancerVac®) | III–IV | II |
NCT00442754 |
|
| Autologous dendritic cells pulsed with p53 peptide | III | II |
NCT00019929 |
|
| Engineered autologous killed tumor cells | IV | I–II |
NCT01159288, NCT02439450 |
|
| Allogeneic CD4+ memory Th1-like T-cells (Allostim®) | II–IV | I–II |
NCT01065441 |
|
| Autologous dendritic cells pulsed with allogenic tumor cells (DVAC/LuCa) | IV | I–II |
NCT02470468 |
|
| Allogenic lymphocytes | I–IV | I | NCT00161187 | |
| Protein vaccine | MUC1 | III | I–II |
NCT01720836, NCT03353675, NCT00415818 NCT03623750 |
| Heat shock protein (gp96-Ig) | III–IV | I | NCT00503568 | |
| Tumor antigen-loaded dendritic cell-derived exosomes | III–IV | II | NCT01159288 | |
| Anti-idiotype vaccine | IIA–III | II | NCT00006470 | |
| Recombinant PRAME protein | I–IIIA | II | NCT01853878 | |
| Peptide vaccine | IDO peptide | III–IV | I | NCT01219348 |
| HLA-A*0201 restricted 9-mer epitopes (Vx001) | IV | II | NCT01935154 | |
| Short lived proteins (SLiPs) and defective ribosomal products (DRiPs) | III–IV | I |
NCT00850785, NCT01909752 |
|
| Synthetic peptides encoding hTERT (UV1) | III | I–II | NCT01789099 | |
| MUC1 peptide (Tecemotide/L-BLP25/Stimuvax®) | III | III |
NCT00409188, NCT00960115, NCT00157196, NCT00828009, NCT00157209 |
|
| UCP2 and UCP4 (telomerase derived peptides) | III | I–II | NCT02818426 | |
| Epitope Peptide Restricted to HLA-A*02 | III–IV | I | NCT01069640, NCT01069575 | |
| GV1001 (Synthetic peptides encoding hTERT) | III | N.E. (already approved in Korea for pancreatic cancer) | NCT00509457 | |
| (MAGE3 epitope) (Astuprotimut-R (GSK-249553)) |
IB–II | II | NCT00290355 | |
| Wilms tumor 1 (WT1) analog peptide (DSP-7888) | III–IV | I | NCT03715985 | |
| Peptides derived from a patient’s tumor individual neo-antigens (NeoPepVac, GRT-C901 and GRT-R902, GEN-009, NEO-PV-01) |
III–IV | I |
NCT03715985, NCT03639714, NCT03794128, NCT03953235, NCT03633110, NCT02897765, NCT03380871 |
|
| Tedopi® (OSE2101) | III–IV | III | NCT02654587 | |
| RAS peptide | II–IV | I–II |
NCT00019006, NCT00019331, NCT00003125 |
|
| Arginase-1 peptide | Generic | I | NCT03689192 | |
| YE-NEO-001 Neoepitope yeast vaccine (YE-NEO-001) | Generic | I | NCT03552718 | |
| MAGE-12 peptide | IV | I | NCT00020267 | |
| Patient specific neoepitopes | ||||
| mRNA vaccine | NY-ESO-1, MAGE C1, 4MAGE C2, TPGB, Survivn, MUC1 (RNActive®) | III–IV | I–II |
NCT03164772, NCT00923312 |
| KRAS gene vaccine V941 (mRNA-5671) | III–IV | I | NCT03948763 | |
| Personalized vaccine against patient’s mutations (RO7198457) | III–IV | I | NCT03289962 | |
| DNA vaccine | NY-ESO-1 plasmid DNA (pPJV7611) to increase immunogenicity of tumor cells |
III–IV | I–II | NCT00199849 |
| Plasmid encoding neoepitopes (VB10.NEO) | III–IV | I–II | NCT03548467 |